ClinicalTrials.gg
CompletedNCT00056160Updated Oct 19, 2017Results posted

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

A Phase 3 interventional study of CC-5013 and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
28th of 373
353 · median 45
Started
2003
with 8 others
Phase 3
53 of 381
3 open now
Registered
15th of 381
by date
Lead sponsor
12 of 381
Celgene

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 28th largest by enrollment of the 373 interventional ones that give a count, is one of 9 that started in 2003, is one of 53 in phase 3, and was the 15th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.

Read the detailed description

This was a phase 3, multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of CC-5013 plus oral pulse high-dose dexamethasone and oral pulse high-dose dexamethasone therapy alone in subjects with relapsed or refractory multiple myeloma. Eligible subjects were randomized in a 1:1 ratio to 1 of 2 treatment groups: Subjects in the CC-5013/Dex treatment group took 25 mg of CC-5013 orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle; Subjects in the Placebo/Dex treatment group took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Subjects in both treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Refractory and Relapsed
  • Revlimid
  • CC5013
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.
  • No more than 3 previous anti-myeloma regimens
  • No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.
  • Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).

Exclusion criteria

Exclusion Criteria:

  • Prior development of disease progression during high-dose dexamethasone containing therapy.
  • Laboratory abnormalities: less than 1,000 cells/mm cubed
  • Laboratory abnormalities: count less than 75,000/mm cubed
  • Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL
  • Laboratory abnormalities: Serum glutamic oxaloacetic transaminase (, aspartate transaminase [AST]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase [ALT])greater than 3.0 x
  • Laboratory abnormalities: Serum total greater than 2.0 mg/dL
  • Prior history of other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.
  • Known to thalidomide or dexamethasone.
  • Development of a desquamating rash while taking thalidomide.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    CC-5013/Dex

    CC-5013 (lenalidomide) plus oral high-dose dexamethasone

    Drug: CC-5013 · Drug: Dexamethasone

  • Experimental
    Placebo/Dex

    Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone

    Drug: Dexamethasone

Interventions

  • Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.

    Also known as: lenalidomide, Revlimid

  • Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Time to Tumor Progression (TTP)

    Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.

    Time frame: 60 weeks (median Time To Progression of CC-5013/Dex treatment group)

Secondary outcomes

  1. Overall Survival

    Overall survival was calculated as the time from randomization to death from any cause.

    Time frame: 170 weeks (median overall survival of CC-5013/Dex treatment group)

  2. Myeloma Response

    The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.

    Time frame: Up to Unblinding (07 Jun 2005)

  3. Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)

    The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.

    Time frame: 30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)

07

Results

Posted Mar 3, 2010
Limitations and caveats
Analyses for efficacy had data cutoff dates of 07 Jun 2005 and a data cutoff date of 23 Jul 2008 for overall survival. Only safety data were collected for 6 subjects ongoing beyond the 23 Jul 2008 data cutoff date.

Participant flow

Subjects in the Placebo/Dex treatment group did not continue participation beyond the period "Up To Unblinding (07 Jun 2005"). Only subjects in the CC-5013/Dex treatment group participated in the period "Extended Follow-up Cutoff (23 Jul 2008)".

Up to Unblinding (07 Jun 2005)
Participant flow — Up to Unblinding (07 Jun 2005)
MilestoneCC-5013/DexPlacebo/Dex
Started177176
Completed6413
Not completed113163
Withdrew: Adverse event3518
Withdrew: Progression of disease57124
Withdrew: Lack of efficacy35
Withdrew: Withdrawal by subject88
Withdrew: Death21
Withdrew: Other87
Extended Follow-up Cutoff (23 Jul 2008)
Participant flow — Extended Follow-up Cutoff (23 Jul 2008)
MilestoneCC-5013/DexPlacebo/Dex
Started1770
Completed60
Not completed1710
Withdrew: Adverse event440
Withdrew: Progression of disease870
Withdrew: Lack of efficacy30
Withdrew: Withdrawal by subject110
Withdrew: Death50
Withdrew: Other210
Final Follow-up
Participant flow — Final Follow-up
MilestoneCC-5013/DexPlacebo/Dex
Started60
Completed00
Not completed60
Withdrew: Transferred into expanded access study.30
Withdrew: Transferred into revassist program20
Withdrew: Adverse event10

Outcome measures

PrimaryTime to Tumor Progression (TTP)

Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.

Time frame:
60 weeks (median Time To Progression of CC-5013/Dex treatment group)
Reported as:
Median · Weeks
Time to Tumor Progression (TTP)
WeeksCC-5013/DexPlacebo/Dex
Time to Tumor Progression (TTP)60.1 (41.1 to 80.0)20.1 (16.1 to 21.1)
SecondaryOverall Survival

Overall survival was calculated as the time from randomization to death from any cause.

Time frame:
170 weeks (median overall survival of CC-5013/Dex treatment group)
Reported as:
Median · Weeks
Overall Survival
WeeksCC-5013/DexPlacebo/Dex
Overall Survival170.1 (142.1 to 204.9)136.4 (104.1 to 176.9)
SecondaryMyeloma Response

The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.

Time frame:
Up to Unblinding (07 Jun 2005)
Reported as:
Number · Participants
Myeloma Response
ParticipantsCC-5013/DexPlacebo/Dex
Myeloma Response10734
SecondaryTime to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)

The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.

Time frame:
30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
Reported as:
Mean · Weeks
Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)
WeeksCC-5013/DexPlacebo/Dex
Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)29.9 ± 30.0215.0 ± 16.98

Adverse events

Collected over Up to 254 weeks (median=48 weeks; mean=77 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CC-5013/Dex—111/177 (62.7%)177/177 (100%)
Placebo/Dex—90/175 (51.4%)175/175 (100%)
Most frequent serious events
Showing 10 of 195
Most frequent serious events
EventCC-5013/DexPlacebo/Dex
PNEUMONIAInfections and infestations30/17715/175
DEEP VEIN THROMBOSISVascular disorders18/1776/175
ATRIAL FIBRILLATIONCardiac disorders10/1771/175
DEHYDRATIONMetabolism and nutrition disorders7/1775/175
PYREXIAGeneral disorders7/1776/175
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders6/1771/175
HYPERCALCAEMIAMetabolism and nutrition disorders2/1775/175
RENAL FAILURERenal and urinary disorders3/1775/175
CEREBROVASCULAR ACCIDENTNervous system disorders5/1771/175
FEBRILE NEUTROPENIABlood and lymphatic system disorders5/1770/175
Most frequent other events
Showing 10 of 110
Most frequent other events
EventCC-5013/DexPlacebo/Dex
FATIGUEGeneral disorders114/177105/175
NEUTROPENIABlood and lymphatic system disorders87/17712/175
DIARRHOEAGastrointestinal disorders85/17753/175
INSOMNIAPsychiatric disorders84/17770/175
CONSTIPATIONGastrointestinal disorders74/17735/175
ANAEMIABlood and lymphatic system disorders72/17737/175
MUSCLE CRAMPMusculoskeletal and connective tissue disorders69/17741/175
UPPER RESPIRATORY TRACT INFECTIONRespiratory, thoracic and mediastinal disorders63/17739/175
NAUSEAGastrointestinal disorders58/17755/175
OEDEMA PERIPHERALGeneral disorders58/17742/175

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CC-5013/DexPlacebo/DexTotal
<=18 years000
Between 18 and 65 years94103197
>=65 years8373156
Age, Continuous
Age, Continuous(years)CC-5013/DexPlacebo/DexTotal
Mean63.3 ± 9.8462.5 ± 9.8162.9 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)CC-5013/DexPlacebo/DexTotal
Female7172143
Male106104210
Region of Enrollment
Region of Enrollment(participants)CC-5013/DexPlacebo/DexTotal
United States142150292
Canada352661
08

Study locations

49 sites
  • Clinical Research Consultants, Inc.
    Hoover, Alabama 35216, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • UCSF California
    San Francisco, California 94143, United States
  • Stanford University Medical Center, Division of Hematology
    Stanford, California 94305-5112, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Mayo Clinic- Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Oncology Hematology Consultants
    Sarasota, Florida 34239, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 33612-9497, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Medical College of Georgia
    Augusta, Georgia 30912-3125, United States
  • Northwestern University Med Ctr
    Chicago, Illinois 60611-2927, United States
  • Rush Cancer Institute Section of Hematology
    Chicago, Illinois 60612-3824, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana Cancer Research Institute
    Indianapolis, Indiana 46202-5254, United States
  • University of Iowa Hospital Clinic
    Iowa City, Iowa 52242, United States
  • Ocshner Clinical Foundation
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins Medicine Department of Oncology
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University Of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine- Sherman Cancer Center
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • MBCCOP Our Lady of Mercy Cancer Center New York Medical College
    The Bronx, New York 10466, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157-1023, United States
  • Cleveland Clinic Myeloma Program
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Kaiser Permanente Northwest Region Center for Health Research
    Portland, Oregon 97227, United States
  • University of Pennsylvania Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Charleston Hematology/Oncology P.A.
    Charleston, South Carolina 29403, United States
  • Medical University of SC
    Charleston, South Carolina 29425, United States
  • South Carolina Oncology Group
    West Columbia, South Carolina 29169, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203-1632, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Froedtert Hospital/BMT Medical College of Wisconsin
    Milwaukee, Wisconsin 53226-3522, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G1Z2, Canada
  • Dalhousie University
    Halifax, Nova Scotia B3H2Y9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5J2M9, Canada
  • Hospital Charles LeMoyne
    Greenfield Park, Quebec J4V2H1, Canada
  • McGill University
    Montreal, Quebec PQH2W1S6, Canada
09

References and documents

Publications

  • Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596. PubMed 18032763 ↗
  • San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120. PubMed 21273172 ↗
  • Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 1;28(1):132-5. doi: 10.1200/JCO.2009.23.0169. Epub 2009 Nov 9. PubMed 19901114 ↗
  • Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17. PubMed 18799726 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2003 to primary completion in Nov 2005, 34 months.

Results were first posted in Mar 2010, 4 years 4 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 34 months is below that.

Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2003
First posted
Mar 7, 2003
StartActual
Jan 1, 2003
Primary completionActual
Nov 1, 2005
CompletionActual
Oct 1, 2008
Results first posted
Mar 3, 2010
Last update
Oct 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00056160
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Mar 7, 2003
Start date
Jan 1, 2003
Primary completion
Nov 1, 2005
Completion
Oct 1, 2008
Results posted
Mar 3, 2010
Last update
Oct 19, 2017

Study contacts

Robert Knight, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion